Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics as the Chinese biotech tacks on preclinical neurological assets to its varied portfolio. Shanghai-based OTR raised the ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Cytokinetics said Chinese regulators approved Myqorzo (formerly aficamten) for the treatment of a serious heart condition ...

These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...

Investing.com -- Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock rose 4.3% in Monday premarket trading following the announcement of two non-exclusive agreements with Pfizer Inc (NYSE:PFE) that ...

Geometric Mean Titers were comparably high at one month post first and second booster. Pfizer aims to submit marketing applications to the FDA and the European Medicines Agency in 2026, subject to ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Its $43 billion acquisition of Seagen in 2023 bolstered ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers ...

Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more. That opens the door for smaller ...